MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Kymera Therapeutics Inc

Abierto

SectorSanidad

33.2 2.15

Resumen

Variación precio

24h

Actual

Mínimo

32.02

Máximo

33.81

Métricas clave

By Trading Economics

Ingresos

-8.3M

-71M

Ventas

3.7M

7.4M

BPA

-0.89

Margen de beneficios

-956.884

Empleados

188

EBITDA

-8.3M

-69M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+80.98% upside

Dividendos

By Dow Jones

Próximas Ganancias

9 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-523M

1.8B

Apertura anterior

31.05

Cierre anterior

33.2

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

Kymera Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

1 nov 2024, 03:00 UTC

Principales Noticias

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners -- WSJ

9 jul 2024, 09:05 UTC

Principales Noticias

These Stocks Are Moving the Most Today: Tesla, Corning, BP, Intel, and More -- Barrons.com

Comparación entre iguales

Cambio de precio

Kymera Therapeutics Inc previsión

Precio Objetivo

By TipRanks

80.98% repunte

Estimación a 12 Meses

Media 55.56 USD  80.98%

Máximo 72 USD

Mínimo 49 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Kymera Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

11 ratings

10

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

25.43 / N/ASoporte y Resistencia

Corto Plazo

Very Strong Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Strong Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.